The Key to Spotting Breakout Biotech Stocks

Download your free report right now and discover how you could catch the next biotech stock surge. Plus, get a FREE subscription to the daily financial email Money Morning. Simply enter your email address in the box below and click ‘Send My FREE Report’.

We will collect and handle your personal information in accordance with our Privacy Policy. You can cancel your subscription at any time.

Dear Reader,

Biotech can be a seriously lucrative market for savvy investors.

Large companies here in Australia, like CSL, have seen massive hikes thanks to successful trials and useful patents. They’ve been rising steadily since the early 2000s with a massive exponential spike this decade.

In the first six months of 2018, that Aussie biotech superstar soared 38%. And they’ve showed no signs of slowing down since.

But there’s even bigger potential in the smaller stocks, yet to make it.

After all, if you’d owned CSL when it was just a tiny starter, you’d be sitting on a cool 26,223% rise by August this year. That means a tiny $500 investment back in 1994 could be sitting at a cool $131,615 (and still growing!)

But this sector is also seriously risky.

The margin for error can be huge, especially with new names in the market.

So when it comes to biotech stocks, it’s important you have a guide to make sure you’re making the right decisions, and that you understand the risk you’re taking on.

That’s where Harje Ronngard comes in.

He’s been following biotech stocks of all levels here on the ASX. So he’s had plenty of time to test out his different tactics and stock sizes.

In a brand new Money Morning report titled ‘The Key to Spotting Breakout Biotech Stocks’, tech investment expert Harje Ronngard reveals where you could find some of the most promising opportunities on the Aussie market.

If you’re looking to add a few promising biotech punts to your portfolio, don’t invest a cent until you read this free special investor report.

You’ll learn:

  • The two types of biotech stocks to look at: Harje outlines the two types of biotech stocks that could serve up potentially lucrative returns. It’s important to choose the type of biotech that suits your portfolio (they’re VERY different).
  • How to approach your chosen style of biotech punt: Once you know which of the two types will work for you, you need to know how to approach them. The considerations for each type are different, but Harje gives a clear blueprint for navigating both.
  • The tactic that could help you deal with this risky sector: Harje’s tactic could help you combat some of the risk associated with this sector. It’s high risk, but there are steps you can take to prepare for that. This is one of his favourites.

Simply put your email address in the space below, and hit ‘Send My FREE Report’. You’ll get a free subscription to Australia’s biggest daily financial email, Money Morning, and we’ll immediately send your free report, ‘The Key to Spotting Breakout Biotech Stocks’.

Download your free report right now and discover how you could catch the next biotech stock surge. Plus, get a FREE subscription to the daily financial email Money Morning. Simply enter your email address in the box below and click ‘Send My FREE Report’.

We will collect and handle your personal information in accordance with our Privacy Policy. You can cancel your subscription at any time.

 

How Money Morning can make you a better, richer investor

Edited by Harje Ronngard, with contributions from Sam Volkering and Greg Canavan, Money Morning isn’t afraid to tell it like it is. From calling politicians out on the big issues, to taking the mighty housing industry on single-handedly, Money Morning exists to cut through the hype and help you make sense of the stories that REALLY make a difference to your wealth.

Harje Ronngard is the lead Editor at Money Morning. With an academic background in finance and investments, Harje knows how simple, yet difficult investing can be. He has worked with a range of assets classes, from futures to equities. But he’s found his niche in equity valuation. There are two questions Harje likes to ask of any investment. What is it worth? And how much does it cost? These two questions alone open up a world of investment opportunities, which Harje shares with Money Morning readers each day.

Harje and the Money Morning team cover share market developments, company announcements and economic events that may affect your wealth. They’ll take anyone to task — banks, governments, big business — if they think someone is trying to pull a fast one with your money.

Whether you agree with Harje, Sam, Greg and the rest of the Money Morning team or not, you’ll find their common-sense, thought-provoking arguments well worth a read — and you’ll soon realise why Money Morning is the biggest circulation daily financial email in Australia.

But don’t take my word for it — start your Money Morning adventure today…

Money Morning is 100% free and delivered to your inbox every morning, six days a week. You’ll never be charged a cent to read it.

Download your free report right now and discover how you could catch the next biotech stock surge. Plus, get a FREE subscription to the daily financial email Money Morning. Simply enter your email address in the box below and click ‘Send My FREE Report’.

We will collect and handle your personal information in accordance with our Privacy Policy. You can cancel your subscription at any time.

No-spam pledge: We will NEVER rent, sell or give away your email address to anyone for any reason. You can unsubscribe from Money Morning anytime, in a few clicks, if you decide you no longer wish to receive it.

All advice is general advice and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Calculating Your Future Returns: The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in this report are forecasts and may not be a reliable indicator of future results. Any potential gains in this do not include taxes, brokerage commissions, or associated fees. Please seek independent financial advice regarding your particular situation. Investments in foreign companies involve risk and may not be suitable for all investors. Specifically, changes in the rates of exchange between currencies may cause a divergence between your nominal gain and your currency-converted gain, making it possible to lose money once your total return is adjusted for currency.

Testimonials

I do admire your straight talking and simple analysis of the situation, I think of you as the Jeremy Clarkson of finance.

JeffreyMoney Morning Reader

Keep up the good independent and well thought out articles offering a view that often debunks mainstream myths.

CraigMoney Morning Reader

Wow what can I say? I was an economically confused moron until I read your newsletter and even though I’ve been a subscriber for a short period I can now see how easy it is to understand, if you use common sense and can have the spin translated into everyday language. Thanks for an entertaining read.

JohnMoney Morning Reader

I think you’re fantastic! I love to read what you write…you’re so interesting and amusing and I’ve learned so much

Chris GaddMoney Morning Reader

You guys are brilliant. I feel more relaxed about the future than ever simply because I know what is going on rather than floundering around with smoke screens and mirrors from the government and mainstream.

Helen CarterMoney Morning Reader
Money Morning Australia